Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Withdrawn 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Lymphoma, T-Cell, Cutaneous 5Lymphoma 5Leukemia, Lymphocytic, Chronic, B-Cell 5Lymphoma, Large B-Cell, Diffuse 4Leukemia, Myeloid, Acute 4Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Neoplasms 3Mycosis Fungoides 3Lymphoma, Mantle-Cell 3Lymphoma, Follicular 3Leukemia 3Congenital Abnormalities 3Thyroid Neoplasms 2Small Cell Lung Carcinoma 2Sezary Syndrome 2Sarcoma 2Myeloproliferative Disorders 2Myelodysplastic-Myeloproliferative Diseases 2Myelodysplastic Syndromes 2Lymphoma, T-Cell, Peripheral 2Lymphoma, T-Cell 2Lung Neoplasms 2Leukemia, Promyelocytic, Acute 2Leukemia, Myelomonocytic, Chronic 2Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 2Colorectal Neoplasms 2Burkitt Lymphoma 2Breast Neoplasms 2Astrocytoma 2Waldenstrom Macroglobulinemia 1

Interventions

fludarabine 2Cyclophosphamide 2romidepsin 1fludarabine phosphate 1duvelisib 1cc-486 1Receptors, Chimeric Antigen 1Ki-1 Antigen 1Doxorubicin 1Automobiles 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Enteropathy-Associated T-Cell Lymphoma × romidepsin × Clear all
NCT04639843 2022-11-04

Doxorubicin, CC-(486) (5-azacitidine), Romidepsin, and Duvelisib (hARD) for T-cell Lymphoma

National Institutes of Health Clinical Center (CC)

Phase 1 Withdrawn
LymphoidOther hematologic neoplasm

Precursor T-Cell Lymphoblastic Leukemia-Lymphoma, Lymphoma, Extranodal NK-T-Cell, Enteropathy-Associated T-Cell Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡